Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting.
暂无分享,去创建一个
Leena Choi | K. Schlendorf | R. Perri | R. Forbes | B. Concepcion | A. Carver | Megan E. Peter | Joshua DeClercq | C. Edmonds | Cori Edmonds
[1] W. Chapman,et al. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[2] M. Schnitzler,et al. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. , 2020, Kidney360.
[3] J. Friedewald,et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. , 2020, Journal of the American Society of Nephrology : JASN.
[4] C. Quintini,et al. Hepatitis C Virus NAT‐Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus–Negative Recipients: A Real‐World Experience , 2020, Hepatology.
[5] R. Sterling,et al. Ultra‐short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] J. Lindenfeld,et al. Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C. , 2019, JAMA cardiology.
[7] B. Tanriover,et al. Short‐term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct‐acting antivirals , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] M. Molnar,et al. Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[9] M. Chattergoon,et al. Lessons from the real world: HCV‐infected donor kidney transplantation as standard practice , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[10] Paul A. Harris,et al. The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.
[11] Snehal R. Patel,et al. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary era. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[12] T. Cotter,et al. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)‐Viremic Donors Into HCV‐Negative Recipients: Outcomes Following Liver Transplant of HCV‐Viremic Donors , 2019, Hepatology.
[13] R. Hasz,et al. Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single‐arm trial , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] R. Sterling,et al. Cost‐effectiveness of hepatitis C–positive donor kidney transplantation for hepatitis C–negative recipients with concomitant direct‐acting antiviral therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] R. Hasz,et al. Twelve-Month Outcomes After Transplant of Hepatitis CInfected Kidneys Into Uninfected Recipients , 2018, Annals of Internal Medicine.
[16] S. Klarenbach,et al. Cost‐effectiveness of using kidneys from hepatitis C nucleic acid test–positive donors for transplantation in hepatitis C–negative recipients , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] D. Segev,et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C VirusInfected Donors to Noninfected Recipients , 2018, Annals of Internal Medicine.
[18] T. Hassanein,et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.
[19] R. Hasz,et al. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. , 2017, The New England journal of medicine.
[20] T. Asselah,et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.
[21] M. Ciarleglio,et al. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade , 2015, PloS one.
[22] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[23] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[24] E. Tuzcu,et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.